Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations

Ahmadi, Alireza; Mohammadnejadi, Elaheh; Razzaghi‐Asl, Nima

doi:10.1016/j.compbiomed.2023.107204

Cited by 4 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The tyrosine kinase activity of EGFR is precisely regulated in normal cells. However, gene mutations can lead to the sustained activation of EGFR and contribute to tumorigenesis ( 77 ). Gefitinib and erlotinib, first-generation small molecule EGFR tyrosine kinase inhibitor targeted drugs extensively used in clinical settings for patients with advanced LUAD, have demonstrated promising efficacy ( 78 , 79 ).…”

Section: Discussionmentioning

confidence: 99%

MIS18A upregulation promotes cell viability, migration and tumor immune evasion in lung adenocarcinoma

Zhu,

Li,

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

MIS18A upregulation promotes cell viability, migration and tumor immune evasion in lung adenocarcinoma

Zhu,

Li,

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

“…Immunotherapy also showed marvelous outcome for LUAD patients by utilizing immune checkpoint inhibitors (ICIs), including anti(a)‐PD‐1, aPD‐L1, and aCTLA‐4 antibodies 5,6 . However, only a part of LUAD patients could respond to targeted therapy and immunotherapy, and drug‐resistance was eventually inevitable 7,8 . Hence, the screen and identification of new biomarkers, especially novel checkpoints with clinical potential, are of great importance and urgent need.…”

Section: Introductionmentioning

confidence: 99%

The expression characteristic and prognostic role of Siglec‐15 in lung adenocarcinoma

Sun,

Du,

et al. 2024

Clinical Respiratory J

View full text Add to dashboard Cite

Sialic acid‐binding immunoglobulin‐like lectin‐15 (Siglec‐15) has been identified as an immune suppressor and a promising candidate for immunotherapy of cancer management. However, the association between Siglec‐15 expression and clinicopathological features of lung adenocarcinoma (LUAD), especially the prognostic role, is not fully elucidated. In this present study, a serial of bioinformatics analyses in both tissue and cell levels were conducted to provide an overview of Siglec‐15 expression. Real‐time quantitative PCR (qPCR) test, western blotting assay, and immunohistochemistry (IHC) analyses were conducted to evaluate the expression of Siglec‐15 in LUAD. Survival analysis and Kaplan–Meier curve were employed to describe the prognostic parameters of LUAD. The results of bioinformatics analyses demonstrated the up‐regulation of Siglec‐15 expression in LUAD. The data of qPCR, western blotting, and IHC analyses further proved that the expression of Siglec‐15 in LUAD tissues was significantly increased than that in noncancerous tissues. Moreover, the expression level of Siglec‐15 protein in LUAD was substantially associated with TNM stage. LUAD cases with up‐regulated Siglec‐15 expression, positive N status, and advance TNM stage suffered a critical unfavorable prognosis. In conclusion, Siglec‐15 could be identified as a novel prognostic biomarker in LUAD and targeting Siglec‐15 may provide a promising strategy for LUAD immunotherapy.

show abstract

Polyphyllin I ameliorates gefitinib resistance and inhibits the VEGF/VEGFR2/p38 pathway by targeting HIF-1a in lung adenocarcinoma

Zhang,

Tian,

Wang

et al. 2024

Phytomedicine

View full text Add to dashboard Cite

Gefitinib derivatives and drug-resistance: A perspective from molecular dynamics simulations

Cited by 4 publications

References 49 publications

MIS18A upregulation promotes cell viability, migration and tumor immune evasion in lung adenocarcinoma

MIS18A upregulation promotes cell viability, migration and tumor immune evasion in lung adenocarcinoma

The expression characteristic and prognostic role of Siglec‐15 in lung adenocarcinoma

Polyphyllin I ameliorates gefitinib resistance and inhibits the VEGF/VEGFR2/p38 pathway by targeting HIF-1a in lung adenocarcinoma

Contact Info

Product

Resources

About